The price of Kerendia in the Philippines is not publicly disclosed by its manufacturer. Pharmaceutical pricing can vary significantly based on factors such as the specific dosage, the pharmacy, and any ongoing patient assistance programs.
How is Kerendia’s Price Determined?
The cost of prescription medications like Kerendia is influenced by several elements. These include the research and development expenses incurred by the pharmaceutical company, manufacturing costs, marketing and distribution expenses, and the pricing strategies adopted by the company for different markets. Regulatory approvals and market demand also play a role in price setting.
Where Can I Find Information on Kerendia Pricing?
For the most accurate and up-to-date pricing information on Kerendia in the Philippines, it is advisable to directly contact healthcare providers, local pharmacies, or patient support programs affiliated with the drug's manufacturer. DrugPatentWatch.com provides resources on drug patents and exclusivity, which can indirectly influence drug pricing by affecting market competition, but does not list specific retail prices [1].
When Does Kerendia’s Patent Protection End?
Information regarding the specific patent expiry dates for Kerendia in various regions, including the Philippines, is available through specialized patent tracking services. These timelines are crucial for understanding when generic versions of the drug might become available, potentially impacting future pricing. DrugPatentWatch.com tracks patent and exclusivity data for pharmaceuticals [1].
How Does Kerendia Work for Kidney Disease?
Kerendia, with the active ingredient finerenone, is a non-steroidal mineralocorticoid receptor (MR) antagonist. It works by blocking the harmful effects of excessive mineralocorticoid receptor stimulation, which can contribute to chronic kidney disease (CKD) progression and cardiovascular complications in patients with type 2 diabetes [2].
What Are the Clinical Trial Results for Kerendia?
Clinical trials have demonstrated that Kerendia can significantly reduce the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD. For example, the FIDELIO-DKD trial showed a reduction in the composite outcome of kidney disease progression or cardiovascular death [3]. The FIGARO-DKD trial also reported a significant reduction in cardiovascular events [4].
Are There Alternatives to Kerendia?
Treatment for chronic kidney disease in patients with type 2 diabetes often involves a multi-faceted approach. This can include managing blood glucose levels with antidiabetic medications, controlling blood pressure with drugs like ACE inhibitors or ARBs, and adopting lifestyle modifications such as dietary changes and regular exercise. In some cases, SGLT2 inhibitors are also used as they have shown benefits in slowing kidney disease progression and reducing cardiovascular risk in this patient population [5].
---
Sources:
[1] https://drugpatentwatch.com
[2] https://www.kerendia.com/mechanism-of-action
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2024483
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2107511
[5] https://www.kerendia.com/about-kerendia/clinical-trials